Eintrag weiter verarbeiten
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , |
| In: | Blood, 125, 2015, 16, S. 2497-2506 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan |
|---|---|
| author |
Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan |
| spellingShingle |
Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan Blood Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Cell Biology Hematology Immunology Biochemistry |
| author_sort |
byrd, john c. |
| spelling |
Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2014-10-606038 <jats:title>Key Points</jats:title> <jats:p>Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade ≥3 cytopenias, fatigue, infections, and adverse events leading to discontinuation.</jats:p> Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Blood |
| doi_str_mv |
10.1182/blood-2014-10-606038 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTEwLTYwNjAzOA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTEwLTYwNjAzOA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 |
| imprint |
American Society of Hematology, 2015 |
| imprint_str_mv |
American Society of Hematology, 2015 |
| issn |
1528-0020 0006-4971 |
| issn_str_mv |
1528-0020 0006-4971 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
byrd2015threeyearfollowupoftreatmentnaiveandpreviouslytreatedpatientswithcllandsllreceivingsingleagentibrutinib |
| publishDateSort |
2015 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_unstemmed |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_full |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_fullStr |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_full_unstemmed |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_short |
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_sort |
three-year follow-up of treatment-naïve and previously treated patients with cll and sll receiving single-agent ibrutinib |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2014-10-606038 |
| publishDate |
2015 |
| physical |
2497-2506 |
| description |
<jats:title>Key Points</jats:title>
<jats:p>Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade ≥3 cytopenias, fatigue, infections, and adverse events leading to discontinuation.</jats:p> |
| container_issue |
16 |
| container_start_page |
2497 |
| container_title |
Blood |
| container_volume |
125 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348912929996818 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:18:23.261Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Three-year+follow-up+of+treatment-na%C3%AFve+and+previously+treated+patients+with+CLL+and+SLL+receiving+single-agent+ibrutinib&rft.date=2015-04-16&genre=article&issn=1528-0020&volume=125&issue=16&spage=2497&epage=2506&pages=2497-2506&jtitle=Blood&atitle=Three-year+follow-up+of+treatment-na%C3%AFve+and+previously+treated+patients+with+CLL+and+SLL+receiving+single-agent+ibrutinib&aulast=O%27Brien&aufirst=Susan&rft_id=info%3Adoi%2F10.1182%2Fblood-2014-10-606038&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348912929996818 |
| author | Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan |
| author_facet | Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan, Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan |
| author_sort | byrd, john c. |
| container_issue | 16 |
| container_start_page | 2497 |
| container_title | Blood |
| container_volume | 125 |
| description | <jats:title>Key Points</jats:title> <jats:p>Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade ≥3 cytopenias, fatigue, infections, and adverse events leading to discontinuation.</jats:p> |
| doi_str_mv | 10.1182/blood-2014-10-606038 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTEwLTYwNjAzOA |
| imprint | American Society of Hematology, 2015 |
| imprint_str_mv | American Society of Hematology, 2015 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229 |
| issn | 1528-0020, 0006-4971 |
| issn_str_mv | 1528-0020, 0006-4971 |
| language | English |
| last_indexed | 2024-03-01T18:18:23.261Z |
| match_str | byrd2015threeyearfollowupoftreatmentnaiveandpreviouslytreatedpatientswithcllandsllreceivingsingleagentibrutinib |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 2497-2506 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Byrd, John C. Furman, Richard R. Coutre, Steven E. Burger, Jan A. Blum, Kristie A. Coleman, Morton Wierda, William G. Jones, Jeffrey A. Zhao, Weiqiang Heerema, Nyla A. Johnson, Amy J. Shaw, Yun Bilotti, Elizabeth Zhou, Cathy James, Danelle F. O'Brien, Susan 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2014-10-606038 <jats:title>Key Points</jats:title> <jats:p>Three-year follow-up of ibrutinib in CLL demonstrated continued activity with durable responses that improve in quality with extended treatment. Toxicity diminished over time with respect to grade ≥3 cytopenias, fatigue, infections, and adverse events leading to discontinuation.</jats:p> Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Blood |
| spellingShingle | Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan, Blood, Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_full | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_fullStr | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_full_unstemmed | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_short | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| title_sort | three-year follow-up of treatment-naïve and previously treated patients with cll and sll receiving single-agent ibrutinib |
| title_unstemmed | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2014-10-606038 |